A Clinical Trial of Adjuvant Intismeran (V940) With or Without Pembrolizumab Coformulated With Berahyaluronidase Alfa (MK-3475A) in High-Risk Stage I Non-Small Cell Lung Cancer (V940-014)
This is not medical advice. AI-assisted translation — inaccuracies may occur. Always verify the original and consult your oncologist before taking any steps.
About the trial
Researchers are looking for new ways to treat high-risk, localized non-small cell lung cancer (NSCLC) that has been removed with surgery. People with high-risk, localized NSCLC are often treated with surgery. Researchers want to learn if participants can receive 1 or 2 trial treatments to help prevent NSCLC from coming back after surgery. One trial medicine is intismeran (also called V940/mRNA-4157) and the other is subcutaneous pembrolizumab (also called SC pembrolizumab and MK-3475A). Intismeran is designed to help a person's immune system attack their specific cancer. SC pembrolizumab is an immunotherapy treatment which helps the immune system fight cancer. The main purpose of this study is to evaluate whether adjuvant intismeran autogene (V940) in combination with SC pembrolizumab and berahyaluronidase alfa (MK-3475A) or intismeran monotherapy improves disease-free survival (DFS) compared with placebo in participants with completely resected high-risk Stage I NSCLC.
Original English text from ClinicalTrials.gov
Who can (and can't) join
✓ Qualifies
- •Rak płuca (NSCLC) wykryty we wczesnym stadium (Etap I) usunięty chirurgicznie.
- •Rak płuca o podwyższonym ryzyku nawrotu po operacji.
- •Brak wcześniejszego leczenia raka poza operacją (np. chemioterapii, radioterapii).
- •Dostarczenie próbki tkanki nowotworowej i próbki krwi z ostatniej operacji.
- •Osoby zakażone wirusem HIV muszą mieć dobrze kontrolowane zakażenie przyjmowanymi lekami.
- •Osoby zakażone wirusem zapalenia wątroby typu B (WZW B) muszą być leczone i mieć niewykrywalną ilość wirusa we krwi.
- •Osoby po przebyciu zakażenia wirusem zapalenia wątroby typu C (WZW C) muszą mieć niewykrywalną ilość wirusa we krwi.
✗ Disqualifies
- •Inny rodzaj raka płuca (np. rak drobnokomórkowy) lub niejednoznaczny typ guza.
- •Znaczące problemy z sercem w ciągu ostatniego roku przed badaniem (np. przebyty zawał, niewydolność serca, poważne choroby zastawek).
Simplified criteria — AI translation
Trial details
- Minimum age
- 18 Years
- Last updated (source)
- July 17, 2026
- Sex
- No restrictions
Therapies / drugs in trial
Locations (35)
Smilow Cancer Center at Yale-New Haven ( Site 3253)
New Haven, United States
Billings Clinic ( Site 3255)
Billings, United States
NHO Revive Research Institute, LLC ( Site 3218)
Lincoln, United States
Renown Regional Medical Center-Renown Health Medical Oncology ( Site 3207)
Reno, United States
White Plains Hospital ( Site 3213)
White Plains, United States
WakeMed Raleigh Campus ( Site 3214)
Raleigh, United States
Altru Health System ( Site 3254)
Grand Forks, United States
The University of Tennessee Medical Center ( Site 3223)
Knoxville, United States
West Virginia University ( Site 3237)
Morgantown, United States
One Clinical Research ( Site 0501)
Nedlands, Australia
Hamilton Health Sciences-Juravinski Cancer Centre ( Site 2506)
Hamilton, Canada
Kingston Health Sciences Centre-Kingston General Hospital Site ( Site 2503)
Kingston, Canada
Centre Hospitalier de l'Université de Montréal ( Site 2501)
Montreal, Canada
European Interbalkan Medical Center-Oncology Department ( Site 5000)
Thessaloniki, Greece
Pecsi Tudomanyegyetem Klinikai Kozpont ( Site 4401)
Pécs, Hungary
Borsod-Abaúj-Zemplén Vármegyei Központi Kórház És Egyetemi Oktatókórház ( Site 4409)
Miskolc, Hungary
Országos Onkológiai Intézet ( Site 4405)
Budapest, Hungary
Rambam Health Care Campus ( Site 3303)
Haifa, Israel
Hadassah Medical Center ( Site 3305)
Jerusalem, Israel
Sheba Medical Center ( Site 3302)
Ramat Gan, Israel
Azienda Ospedaliero Universitaria Maggiore della Carità ( Site 2803)
Novara, Italy
Ziekenhuis St. Jansdal ( Site 4800)
Harderwijk, Netherlands
Radboudumc ( Site 4806)
Nijmegen, Netherlands
Frisius Medisch Centrum ( Site 4808)
Leeuwarden, Netherlands
Meander Medisch Centrum ( Site 4802)
Amersfoort, Netherlands
University Medical Center Groningen ( Site 4807)
Groningen, Netherlands
Wielkopolskie Centrum Pulmonologii i Torakochirurgii ( Site 4202)
Poznan, Poland
IP Clinic ( Site 4204)
Lodz, Poland
Hospital Universitario Virgen Macarena ( Site 0306)
Seville, Spain
Chang Gung Memorial Hospital at Kaohsiung ( Site 5302)
Kaohsiung City, Taiwan
China Medical University Hospital ( Site 5303)
Taichung, Taiwan
Taichung Veterans General Hospital ( Site 5301)
Taichung, Taiwan
National Cheng Kung University Hospital ( Site 5300)
Tainan, Taiwan
Taipei Medical University Hospital ( Site 5305)
Taipei, Taiwan
Hacettepe Universite Hastaneleri-oncology hospital ( Site 4300)
Ankara, Turkey (Türkiye)
Trial contact
Toll Free Number
Contact information from ClinicalTrials.gov. Contact in English.
Share this trial
Data from ClinicalTrials.gov. AI-assisted translation, last sync: 7/7/2026.
You can help another person
We fund the Radar, this site, and the development of our Grosz dla Życia fundraising platform from donations and our own resources. Every contribution, even a small one, really helps.